Navigation Links
Fibrocell Science, Inc. Initiates Histology Study of azficel-T
Date:5/13/2010

EXTON, Pa., May 13 /PRNewswire-FirstCall/ --  Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the initiation of a small histology study (IT-H-001) of azficel-T, an autologous cell therapy currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe nasolabial fold wrinkles.  The study has a target enrollment of approximately 20 participants from the completed and statistically significant pivotal Phase III studies of azficel-T (IT-R-005 and IT-R-006).

The FDA requested the comparative histological data from this study in a Complete Response letter issued to the Company on December 21, 2009 related to the Biologics License Application (BLA) for azficel-T for the treatment of moderate to severe nasolabial fold wrinkles in adults.  

The histology study will evaluate tissue treated with azficel-T as compared to tissue treated with sterile saline (placebo).  The study will also provide information about the skin after treatment, including evaluation of collagen and elastin fibrils, and cellular structure of the sampled tissues.

"Over the past several months, we have worked closely with the FDA and our clinical investigators to design this study protocol," said David Pernock, Chairman and CEO, Fibrocell Science Inc.  "We intend to submit data from the study to the FDA in the fourth quarter of 2010."

According to milestones established in the Prescription Drug User Fee Act (PDUFA), the FDA will have six months to review the data submission once they deem Fibrocell's response to their letter complete.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence.  For additional information, please visit www.fibrocellscience.com .

Forward Looking Statements  

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, without limitation, the ability of the Company to submit data from the study to the FDA in the fourth quarter of 2010 as part of its Complete Response and the timely acceptance by the FDA of the Company's Complete Response. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's public filings with the SEC.


'/>"/>
SOURCE Fibrocell Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Fibrocell Science, Inc. Enters Into Financing Agreement
2. Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
3. Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for Wrinkles
4. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
5. Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.
6. California Life Science, Business, and Economic Development Experts Discuss Californias Bioscience Future
7. FRC: NIH Stem Cell Guidelines Reflect Poor Science, Ignore Real Hope for Patients
8. Seahorse Bioscience, Inc. Acquires BioProcessors Corp.
9. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
10. For creating new field of science, Texas chemist wins international prize
11. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Research and Markets has announced the addition of ... and Companies" to their offering. ... The number of companies ... few years. More than 1,000 companies have been identified to ... are profiled in the report along with tabulation of 811 ...
(Date:1/17/2017)... ... 17, 2017 , ... One Million Solutions in Health announces, ... in investment towards 15+ TEC Validation Projects™. As a pre-competitive consortium, SafeTEC ... drug safety assessment, for the industry as a whole. , Through the SafeTEC ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... publication its decision on the appeal filed by India-based Dishman Pharmaceutical & Chemical ... contract against DPCL and one of its Dishman Group’s 100% wholly owned New ...
(Date:1/14/2017)... Jan. 13, 2017  The Alliance for Safe Biologic ... to FDA final guidance on biologic naming: ... leadership in emphasizing the importance of distinct naming for ... of the benefits biosimilars will bring to patients, including ... Yet the portion of the Guidance dealing with suffix ...
Breaking Biology Technology:
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market by ... Area, End User, And Region - Global Forecast to 2021", published by MarketsandMarkets, ... to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate (CAGR) ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... offering of €500.0 million principal amount of its 1.414% senior ... its 2.425% senior unsecured notes due 2026. ... December 13, 2016, subject to the satisfaction of customary closing conditions.  ... The Company intends to use the ...
Breaking Biology News(10 mins):